Wealth Manager - the site for professional investment managers

Register to get unlimited access to Citywire’s fund manager database. Registration is free and only takes a minute.

Woodford to meet Pfizer chief about AstraZeneca deal

Woodford to meet Pfizer chief about AstraZeneca deal

Neil Woodford is to meet the chief executive of Pfizer to discuss its bid for AstraZeneca.

According to Sky News, the star fund manager will sit down with Ian Read, the US giant’s boss, to talk through his concerns about the deal.

Woodford (pictured) has been a long-term backer of AstraZeneca and earlier this month said that he believes the company ‘has an exciting future as an independent entity’.

AstraZeneca rejected an improved offer of £63 billion, saying the amount ‘significantly undervalued AstraZeneca and its prospects’.

The stock is expected to be a key component of the newly launched Woodford Investment Management’s Income fund, which comes to market next month.

It is set to be another busy week for Read who today goes before MPs on the Business, Innovation and Skills Select Committee to discuss his plans for the combined business, should a deal go through. A number of politicians have raised concerns about the potential loss of jobs following a merger.

Yesterday Axa Framlington's AA-rated Nigel Thomas said that he been buying AstraZeneca shares ahead of the bid aproach, feeling its advances in cancer treatments was undervalued by the market.

He said: 'While approaching the subject as a layman, the basic tenet of the research is that cancer can be transformed from a terminal illness to a chronic disease through immunotherapy.

‘We have purchased shares in AstraZeneca in the last six months; their predicament of significant revenue-earning patent expiries over the next few years has been heavily discounted by the stock market.

‘However, behind the other three companies, Astra’s portfolio of compounds is notable due to their expertise, with existing drugs across a wide spread of clinical outcomes. Given that many immunotherapies will incorporate other drugs in "combination therapies", AstraZeneca will have the option to commercialise a great deal of in-house compounds to late stage trials.'

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.

Related Fund Managers

Nigel Thomas
Nigel Thomas
90/147 in Equity - UK (All Companies) (Performance over 3 years) Average Total Return: 35.00%
Neil Woodford
Neil Woodford
18/80 in Equity - UK Equity Income (Performance over 3 years) Average Total Return: 51.83%
Citywire TV
Play Kames' CIO: US bowed to international pressure

Kames' CIO: US bowed to international pressure

Stephen Jones, chief investment officer of Kames Capital, said the US domestic economy passed the test, but international concerns weighed heavy.

Play Sector Spotlight: Thomas Miller's Jordan Sriharan on bonds

Sector Spotlight: Thomas Miller's Jordan Sriharan on bonds

With the US interest rates on hold for now, we suss out how wealth managers are managing their fixed income exposure in this environment.

Brewin's Foster: debating 'Corbynomics'

Brewin's Foster: debating 'Corbynomics'

This week Brewin Dolphin's head of research discusses Jeremy Corbyn's policies and their economic impact 

Wealth Manager on Twitter